Your browser doesn't support javascript.
loading
EXCI-CEST: Exploiting pharmaceutical excipients as MRI-CEST contrast agents for tumor imaging.
Longo, Dario Livio; Moustaghfir, Fatima Zzahra; Zerbo, Alexandre; Consolino, Lorena; Anemone, Annasofia; Bracesco, Martina; Aime, Silvio.
Afiliación
  • Longo DL; Istituto di Biostrutture e Bioimmagini (IBB), Consiglio Nazionale delle Ricerche (CNR), Via Nizza 52, 10126, Torino, Italy. Electronic address: dario.longo@unito.it.
  • Moustaghfir FZ; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy.
  • Zerbo A; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy.
  • Consolino L; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy.
  • Anemone A; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy.
  • Bracesco M; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy.
  • Aime S; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, Via Nizza 52, 10126, Torino, Italy.
Int J Pharm ; 525(1): 275-281, 2017 Jun 15.
Article en En | MEDLINE | ID: mdl-28433532
ABSTRACT
Chemical Exchange Saturation Transfer (CEST) approach is a novel tool within magnetic resonance imaging (MRI) that allows visualization of molecules possessing exchangeable protons with water. Many molecules, employed as excipients for the formulation of finished drug products, are endowed with hydroxyl, amine or amide protons, thus can be exploitable as MRI-CEST contrast agents. Their high safety profiles allow them to be injected at very high doses. Here we investigated the MRI-CEST properties of several excipients (ascorbic acid, sucrose, N-acetyl-d-glucosamine, meglumine and 2-pyrrolidone) and tested them as tumor-detecting agents in two different murine tumor models (breast and melanoma cancers). All the investigated molecules showed remarkable CEST contrast upon i.v. administration in the range 1-3ppm according to the type of mobile proton groups. A marked increase of CEST contrast was observed in tumor regions up to 30min post injection. The combination of marked tumor contrast enhancement and lack of toxicity make these molecules potential candidates for the diagnosis of tumors within the MRI-CEST approach.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Imagen por Resonancia Magnética / Medios de Contraste / Excipientes / Neoplasias Idioma: En Revista: Int J Pharm Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Imagen por Resonancia Magnética / Medios de Contraste / Excipientes / Neoplasias Idioma: En Revista: Int J Pharm Año: 2017 Tipo del documento: Article